TY  - GEN
AU  - Keefer,M C
AU  - Graham,B S
AU  - McElrath,M J
AU  - Matthews,T J
AU  - Stablein,D M
AU  - Corey,L
AU  - Wright,P F
AU  - Lawrence,D
AU  - Fast,P E
AU  - Weinhold,K
AU  - Hsieh,R H
AU  - Chernoff,D
AU  - Dekker,C
AU  - Dolin,R
TI  - Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group
SN  - 0889-2229
PY  - 1996///1010
KW  - AIDS Vaccines
KW  - administration & dosage
KW  - Adjuvants, Immunologic
KW  - Adolescent
KW  - Adult
KW  - Amino Acid Sequence
KW  - Cells, Cultured
KW  - Consumer Product Safety
KW  - Dose-Response Relationship, Immunologic
KW  - Double-Blind Method
KW  - Female
KW  - HIV Antibodies
KW  - blood
KW  - HIV Envelope Protein gp120
KW  - immunology
KW  - HIV Infections
KW  - HIV-1
KW  - Humans
KW  - Leukocytes, Mononuclear
KW  - cytology
KW  - Male
KW  - Middle Aged
KW  - Molecular Sequence Data
KW  - Polysorbates
KW  - Squalene
KW  - T-Lymphocytes, Cytotoxic
KW  - Vaccines, Synthetic
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1089/aid.1996.12.683
ER  -